Type 1 diabetes is an autoimmune disease in which your immune system destroys the cells in your pancreas that produce insulin. Without insulin, glucose from food stays trapped in your bloodstream instead of entering your cells for energy. About 5% to 10% of all diabetes cases are type 1, and unlike type 2, it has nothing to do with diet or lifestyle.
What the Immune System Attacks
Your pancreas contains clusters of cells called islets, and within those islets are beta cells, the only cells in your body that make insulin. In type 1 diabetes, your immune system misidentifies these beta cells as foreign invaders and sends immune cells to destroy them. This process, called autoimmune destruction, usually unfolds over months or years before you notice any symptoms. By the time blood sugar levels rise enough to cause problems, roughly 80% to 90% of your beta cells are already gone.
Researchers can detect this attack long before symptoms appear by testing for specific antibodies in the blood. Four autoantibodies are used in screening: antibodies against an enzyme called GAD (found in 50% to 80% of patients at diagnosis), antibodies against insulin itself (50% to 90%), antibodies targeting a protein called IA-2 (30% to 70%), and antibodies against a zinc transporter on beta cells (50% to 70%). Having two or more of these antibodies means the autoimmune process is already underway, even if blood sugar is still normal.
Why the Immune System Turns on Itself
The exact trigger remains unclear, but genetics load the gun. Certain gene variants in the immune system’s identification machinery dramatically increase risk. The highest-risk combination is a specific pairing of two gene variants (known as DR3 and DR4), which helps explain why type 1 diabetes runs in families. Still, most people with these gene variants never develop the disease, which means something in the environment has to pull the trigger.
Suspected environmental triggers include viral infections, particularly certain common childhood viruses that may either damage beta cells directly or confuse the immune system into attacking them. Dietary factors in early infancy have also been studied, though no single food or exposure has been confirmed as a definitive cause. One important nuance: these environmental exposures are likely so common that nearly everyone encounters them. The difference is that only people with the right genetic susceptibility develop the autoimmune response.
What Happens Without Insulin
Insulin works like a key that unlocks the doors of your cells so glucose can enter. Without it, glucose accumulates in the blood while your cells starve. This triggers the classic early symptoms: extreme thirst, frequent urination (your kidneys try to flush the excess sugar), unexplained weight loss, and fatigue.
When cells can’t access glucose, your body switches to breaking down fat for fuel. This produces acidic byproducts called ketones. In small amounts, ketones are harmless. But without any insulin, ketone production spirals out of control, and they build up faster than your body can clear them. This is diabetic ketoacidosis, or DKA, a medical emergency that can develop within hours. Symptoms include nausea, abdominal pain, fruity-smelling breath, and confusion. DKA is often the event that leads to a type 1 diabetes diagnosis, especially in children.
How It Differs From Type 2 Diabetes
The core difference is straightforward. In type 1, your body makes no insulin (or almost none). In type 2, your body makes insulin but your cells stop responding to it properly. Think of it this way: type 1 means the key is missing entirely, while type 2 means the key exists but the lock is sticky and doesn’t turn easily.
People with type 2 diabetes often still produce significant insulin for years or even decades, and many manage the condition initially with oral medications, exercise, and dietary changes. None of that works in type 1, because the fundamental problem is a total lack of insulin production. From the moment of diagnosis, people with type 1 diabetes need insulin from an external source to survive. Type 2 also tends to develop gradually in adults, often alongside obesity, while type 1 most commonly appears in childhood or adolescence, though it can strike at any age.
The Honeymoon Phase
Shortly after diagnosis and the start of insulin therapy, many people with type 1 diabetes experience a surprising reprieve. Their blood sugar becomes easier to manage, and they need less insulin than expected. This is called the honeymoon phase, or remission period.
It happens because not all beta cells are dead at diagnosis. Once you start taking insulin, it gives the surviving beta cells a chance to rest and partially recover. Correcting the high blood sugar also removes a toxic environment (sometimes called glucotoxicity) that was accelerating beta cell damage. During this window, the remaining beta cells rally and produce enough insulin to reduce your external insulin needs.
The honeymoon phase is temporary. The autoimmune attack hasn’t stopped, just slowed. Over weeks to months, sometimes up to a year or more, the immune system continues destroying the remaining beta cells until insulin production drops to essentially zero. Understanding this phase matters because a sudden improvement after diagnosis doesn’t mean the diabetes is going away.
Living With Insulin Replacement
Managing type 1 diabetes means replacing what your pancreas can no longer make. This requires balancing different types of insulin throughout the day to mimic what a healthy pancreas does automatically.
Long-acting insulin, which takes about 2 hours to start working and lasts up to 24 hours without a peak, provides a steady background level. This covers the glucose your liver releases between meals and overnight. On top of that, rapid-acting insulin is taken before meals. It kicks in within 15 minutes, peaks at about 1 hour, and is gone within 2 to 4 hours, covering the surge of glucose from food. Some people use an inhaled form that works even faster, starting in 10 to 15 minutes.
Many people with type 1 diabetes use an insulin pump, a small device worn on the body that delivers a continuous trickle of rapid-acting insulin through a tiny tube under the skin. The pump can be programmed to increase or decrease the flow at different times of day, and you press a button to deliver extra insulin at meals. Newer systems pair the pump with a continuous glucose monitor and use an algorithm to adjust insulin delivery automatically, sometimes called a closed-loop or artificial pancreas system. These don’t eliminate the need for attention, but they significantly reduce the mental burden of constant decision-making.
What High Blood Sugar Does Over Time
Even with good management, blood sugar in type 1 diabetes fluctuates more than in someone without the condition. Over years, periods of elevated blood sugar damage blood vessels throughout the body. The damage falls into two categories based on which blood vessels are affected.
Small blood vessel damage (microvascular) is responsible for the complications most associated with diabetes. In the eyes, excess glucose triggers oxidative stress and inflammation in the tiny vessels of the retina, eventually causing bleeding, swelling, and abnormal new vessel growth that can lead to vision loss. In the kidneys, similar damage to the filtering units gradually impairs their ability to clean the blood. In nerves, particularly in the feet and hands, high glucose disrupts normal nerve function, causing numbness, tingling, or pain.
Large blood vessel damage (macrovascular) increases the risk of heart disease and stroke. People with type 1 diabetes have a significantly higher cardiovascular risk than the general population, even at younger ages. This is why blood pressure and cholesterol management matter alongside blood sugar control.
The consistent finding across decades of research is that tighter blood sugar control substantially reduces the risk of all these complications. This doesn’t mean perfection is required, but it does mean that the daily effort of managing blood sugar has real, measurable payoffs over time.
Newer Approaches to Slowing the Disease
For the first time, a treatment exists that can delay the onset of type 1 diabetes before it fully develops. An immunotherapy drug approved in 2022 targets specific immune cells involved in the autoimmune attack on beta cells. In clinical trials, people at high risk (those with autoantibodies and early blood sugar abnormalities but not yet diagnosed) who received the treatment went a median of nearly 5 years before developing clinical diabetes, compared to about 2 years for those who received a placebo. That’s roughly 2 to 3 extra years of life without needing daily insulin.
This treatment is designed for a very specific window: people identified through autoantibody screening who are in the early stages of the autoimmune process but still have enough beta cell function to preserve. It doesn’t cure the disease or stop it permanently, but delaying onset by years is meaningful, particularly for children, where each year of simpler management during development matters.